Skip to main content

Brannan Stephen K.'s Form 4 filing

Karuna Therapeutics, Inc. (KRTX) · filed Oct 10, 2023

Accession no.
0000950170-23-052671
Filed
Oct 10, 2023
Trade date
Oct 9, 2023
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $866.2K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brannan Stephen K.CIK 0001777631Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 9, 2023Common StockMOption exerciseAcquired+2,500$5.45+$13,62531,150Direct
Oct 9, 2023Common StockMOption exerciseAcquired+5,000$131.64+$658,20036,150Direct
Oct 9, 2023Common StockSSaleDisposed−3,256$172.96F2−$563,157.7632,894Direct
Oct 9, 2023Common StockSSaleDisposed−1,744$173.77F3−$303,054.8831,150Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 9, 2023Common StockMOption exerciseDisposed−2,500$0.00$017,177Direct
Oct 9, 2023Common StockMOption exerciseDisposed−5,000$0.00$036,350Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.40 to $173.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.42 to $174.33, inclusive.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)